Alpha Teknova, Inc. reported a revenue of $11.1 million for the first quarter of 2026, marking a 13.1% increase from $9.8 million in the same period of 2025. The growth was primarily driven by a significant rise in Clinical Solutions revenue, which surged by 84.6% to $2.1 million, while Lab Essentials revenue increased modestly by 3.4% to $8.4 million. The company's gross profit also improved, reaching $3.8 million, up 25.8% from $3.0 million a year earlier, resulting in a gross profit margin of 34.2%, compared to 30.7% in the prior year.
Despite the increase in revenue, Alpha Teknova reported an operating loss of $4.3 million for the first quarter of 2026, a slight improvement from the $5.0 million loss recorded in the same quarter of 2025. Total operating expenses rose marginally to $8.1 million, up from $8.0 million, with notable increases in sales and marketing expenses, which grew by 29.8% to $2.1 million. General and administrative expenses decreased by 7.9% to $5.1 million, reflecting lower stock-based compensation and professional fees.
The company’s balance sheet as of March 31, 2026, showed total assets of $98.7 million, down from $103.6 million at the end of 2025. Current assets decreased to $31.7 million, primarily due to a reduction in cash and cash equivalents, which fell to $4.3 million from $5.9 million. Total liabilities also decreased slightly to $33.7 million, with long-term debt remaining relatively stable at $13.2 million. The company’s accumulated deficit increased to $140.3 million, reflecting ongoing operational losses.
Alpha Teknova continues to focus on strategic initiatives to enhance its market presence and operational efficiency. The company is investing in its workforce and infrastructure, including the ramp-up of a new warehouse and distribution facility. Additionally, it aims to strengthen its brand through targeted marketing and expanded sales efforts. The company remains vigilant regarding broader economic trends, including inflation and interest rate fluctuations, which could impact customer demand and operational costs.
Looking ahead, Alpha Teknova anticipates that while expenses may continue to rise, they will do so at a slower rate as the company implements its growth strategies. The management remains committed to improving operational efficiency and expanding capacity to support revenue growth across existing and new markets. The company is also in compliance with its financial covenants under its credit agreement, providing a stable foundation for its future operations.
About Alpha Teknova, Inc.
Alpha Teknova, Inc. manufactures custom chemical reagents and media critical for life sciences research, drug development, and molecular diagnostics. Serving pharmaceutical, biotechnology, diagnostics, and academic customers, it offers pre-poured media plates, cell culture media, and molecular biology reagents. Its adaptable manufacturing processes enable rapid, scalable production of research-use and GMP-grade products, supporting customers from discovery through commercialization with high quality, fast turnaround, and regulatory compliance.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.